ETS2-AS1: A Potential Drug Target and Biomarker (G400867)
ETS2-AS1: A Potential Drug Target and Biomarker
ETS2-AS1 (ETS2 antisense RNA 1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure, function, and expression patterns make it an attractive candidate for further research and development as a drug or biomarker.
Structure and Function
ETS2-AS1 is a small non-coding RNA molecule that contains 189 amino acid residues. It has a unique feature, known as a double-stranded RNA structure, which is composed of two complementary strands that are held together by a disulfide bond. This structure gives ETS2-AS1 a unique stability and stability, and allows it to interact with other molecules in the cell.
ETS2-AS1 functions as an antisense RNA, which means it blocks the function of a specific mRNA by binding to its target RNA and preventing it from being translated into protein. This unique mechanism of action makes ETS2-AS1 an attractive candidate as a drug target or biomarker.
Expression and regulation
ETS2-AS1 is expressed in various tissues and cells in the body, including the brain, heart, liver, and pancreas. Its expression levels vary depending on the specific cell type and the environment in which it is expressed. ETS2-AS1 has been shown to be expressed at different levels in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, which suggest that it may have a role in the development and progression of these diseases.
In addition, ETS2-AS1 has been shown to be expressed at different levels in various cancer types, including breast, lung, and ovarian cancer. This suggests that it may be a potential biomarker for cancer and could be a target for cancer therapies.
Drug targeting
ETS2-AS1's unique structure and function make it an attractive candidate for drug targeting. Drugs that target ETS2-AS1 have the potential to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
For example, drugs that target ETS2-AS1 have been shown to be effective in treating breast cancer. One study found that inhibiting ETS2-AS1 expression using small interfering RNA (siRNA) led to a significant reduction in the growth of human breast cancer cells, suggesting that ETS2-AS1 may be a potential drug target for breast cancer.
Another example is the treatment of neurodegenerative diseases, such as Alzheimer's disease, which is a progressive neurological disorder that affects millions of people worldwide. Drugs that target ETS2-AS1 have been shown to improve the cognitive function and reduce the number of neurofibrillary tangles in the brains of individuals with Alzheimer's disease.
ETS2-AS1 as a biomarker
ETS2-AS1 has also been shown to be a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique expression patterns and functions make it an attractive candidate for use as a biomarker.
For example, ETS2-AS1 has been shown to be expressed at different levels in various cancer types, including breast, lung, and ovarian cancer. This suggests that it may be a potential biomarker for cancer and could be used to diagnose and monitor the effectiveness of cancer therapies.
In addition, ETS2-AS1 has been shown to be expressed at different levels in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This suggests that it may be a potential biomarker for these diseases and could be used to diagnose and monitor the progression of these conditions.
Conclusion
ETS2-AS1 is a unique non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases. Its
Protein Name: ETS2 Antisense RNA 1
The "ETS2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ETS2-AS1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ETV1 | ETV2 | ETV3 | ETV3L | ETV4 | ETV5 | ETV6 | ETV7 | Eukaryotic translation initiation factor 2-alpha kinase | Eukaryotic translation initiation factor 2B | Eukaryotic translation initiation factor 3 (eIF-3) complex | Eukaryotic Translation Initiation Factor 4A (eIF-4A) | Eukaryotic Translation Initiation Factor 4E Binding Protein | EVA1A | EVA1A-AS | EVA1B | EVA1C | EVC | EVC2 | EVI2A | EVI2B | EVI5 | EVI5L | EVL | EVPL | EVPLL | EVX1 | EVX1-AS | EVX2 | EWSAT1 | EWSR1 | EXD1 | EXD2 | EXD3 | EXO1 | EXO5 | EXOC1 | EXOC1L | EXOC2 | EXOC3 | EXOC3-AS1 | EXOC3L1 | EXOC3L2 | EXOC3L4 | EXOC4 | EXOC5 | EXOC5P1 | EXOC6 | EXOC6B | EXOC7 | EXOC8 | Exocyst complex | EXOG | EXOGP1 | Exon junction complex | EXOSC1 | EXOSC10 | EXOSC10-AS1 | EXOSC2 | EXOSC3 | EXOSC4 | EXOSC5 | EXOSC6 | EXOSC7 | EXOSC8 | EXOSC9 | Exosome Complex | EXPH5 | EXT1 | EXT2 | EXTL1 | EXTL2 | EXTL2P1 | EXTL3 | EXTL3-AS1 | EYA1 | EYA2 | EYA3 | EYA4 | EYS | EZH1 | EZH2 | EZHIP | EZR | F10 | F11 | F11-AS1 | F11R | F12 | F13A1 | F13B | F2 | F2R | F2RL1 | F2RL2 | F2RL3 | F3 | F5 | F7 | F8
